Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.51 |
| ▸ | RAB9A | P51151 | 2/20 | 0.48 |
| ▸ | PRKCI | P41743 | 1/20 | 0.47 |
| ▸ | KDM1A | O60341 | 1/20 | 0.47 |
| ▸ | MAOA | P21397 | 1/20 | 0.47 |
| ▸ | MAOB | P27338 | 1/20 | 0.47 |
| ▸ | NPC1 | O15118 | 1/20 | 0.47 |
| ▸ | POLB | P06746 | 1/20 | 0.47 |
| ▸ | TAS1R3 | Q7RTX0 | 1/20 | 0.44 |
| ▸ | TAS1R1 | Q7RTX1 | 1/20 | 0.44 |
| ▸ | KCNH2 | Q12809 | 4/20 | 0.44 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13262203 | 0.89 | KDM4E (0.43) | KDM4ERAB9APRKCIKDM1AMAOA | |
| SCHEMBL5023473 | 0.89 | CTNNB1 (0.46) | KDM4ERAB9APRKCIKDM1AMAOA | |
| SCHEMBL12647718 | 0.86 | DYRK1A (0.54) | KDM4ERAB9ANPC1KCNH2DYRK1A | |
| SCHEMBL1276487 | 0.85 | RAB9A (0.46) | RAB9APRKCIKDM1AMAOAMAOB | |
| SCHEMBL8167072 | 0.85 | CHRM2 (0.54) | KDM4EKCNH2 | |
| SCHEMBL14015076 | 0.82 | RAB9A (0.44) | RAB9APRKCIKDM1AMAOAMAOB | |
| SCHEMBL24196244 | 0.82 | FABP4 (0.47) | KDM4ERAB9ANPC1DYRK1A | |
| Ethyne SCHEMBL27313736 | 0.81 | CHRM2 (0.51) | KDM4EKCNH2 | |
| SCHEMBL13461945 | 0.81 | RAB9A (0.46) | RAB9APRKCIKDM1AMAOAMAOB | |
| SCHEMBL13632598 | 0.81 | RAB9A (0.52) | RAB9APRKCIKDM1AMAOAMAOB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 288 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-115850002-B | Method for hydrodehalogenating halogenated alkane | 中国科学院兰州化学物理研究所 | 2025-05-23 | — | — | CN | disclosed |
| EP-2925139-B1 | FERMENTED SOIL ADDITIVE | LIQUID FERTILISER SYSTEMS PTY LTD (AU) | 2025-04-30 | — | — | EP | disclosed |
| US-20240216355-A1 | PHARMACEUTICAL COMPOSITIONS FOR USE IN THE PREVENTION AND TREATMENT OF A DISEASE OR DISORDER CAUSED BY OR ASSOCIATED WITH ONE OR MORE PREMATURE TERMINATION CODONS | MONTE ROSA THERAPEUTICS AG (CH) | 2024-07-04 | — | — | US | disclosed |
| US-11912682-B2 | Isoindolinone compounds | MONTE ROSA THERAPEUTICS, INC. (US) | 2024-02-27 | — | — | US | disclosed |
| US-20230365531-A1 | INHIBITORS OF HUMAN RESPIRATORY SYNCYTIAL VIRUS AND METAPNEUMO VIRUS | MERCK SHARP & DOHME LLC (US) | 2023-11-16 | — | — | US | disclosed |
| US-20230348418-A1 | ISOINDOLINONE COMPOUNDS | MONTE ROSA THERAPEUTICS AG (CH) | 2023-11-02 | — | — | US | disclosed |
| US-20230312499-A1 | CARBAMATE COMPOUNDS AND METHODS OF MAKING AND USING SAME | H. LUNDBECK A/S (DK) | 2023-10-05 | — | — | US | disclosed |
| WO-2023146990-A1 | COMPOUNDS AND METHODS OF USE | TANGO THERAPEUTICS, INC. (US) | 2023-08-03 | — | — | WO | disclosed |
| US-20230183219-A1 | CONDENSED SUBSTITUTED HYDROPYRROLES AS ANTAGONISTS OF THE MUSCARINIC ACETYLCHOLINE RECEPTOR M4 | VANDERBILT UNIVERSITY | 2023-06-15 | — | — | US | disclosed |
| US-20230183237-A1 | COMPETITIVE AND NONCOMPETITIVE INHIBITORS OF THE MUSCARINIC ACETYLCHOLINE RECEPTOR M5 | VANDERBILT UNIVERSITY | 2023-06-15 | — | — | US | disclosed |
| US-20070078120-A1 | Novel piperidine derivative | DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) | 2007-04-05 | — | — | US | disclosed |
| WO-2007026959-A2 | DERIVATIVES OF 4-PIPERAZIN-1-YL-4-BENZ0 [B] THIOPHENE SUITABLE FOR THE TREATMENT OF CNS DISORDERS | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2007-03-08 | — | — | WO | disclosed |
| US-20070037855-A1 | Compounds for inhibiting beta-amyloid production and methods of identifying the compounds | ALZHEIMER'S INSTITUTE OF AMERICA, INC. | 2007-02-15 | — | — | US | disclosed |
| US-20070037851-A1 | Inhibits binding of CCR3 ligands such as eotaxins to their target cells; inhibits physiological effects of binding; therapeutic and prophylactic agents for asthma, rhinitis, dermatitis, urticaria, conjunctivitis, inflammatory bowel; tissue infiltration of eosinophils, basophils, activated T cells | TEIJIN LIMITED, A JAPANESE BODY CORPORATE (JP) | 2007-02-15 | — | — | US | disclosed |
| US-20070032525-A1 | Piperidine derivatives having ccr3 antagonism | TEIJIN LIMITED, A JAPANESE BODY CORPORATE (JP) | 2007-02-08 | — | — | US | disclosed |
| US-7169775-B2 | Amino methyl imidazoles as C5a receptor modulators | NEUROGEN CORPORATION (US) | 2007-01-30 | — | — | US | disclosed |
| US-20070010509-A1 | Cycloamine ccr5 receptor antagonists | TEIJIN PHARMA LIMITED (JP) | 2007-01-11 | — | — | US | disclosed |
| US-20050159469-A1 | HIV protease inhibiting compounds | ABBVIE INC. | 2005-07-21 | — | — | US | disclosed |
| EP-1277741-A1 | CYCLIC COMPOUNDS | TANABE SEIYAKU CO., LTD. (JP) | 2003-01-22 | — | — | EP | disclosed |
| EP-0462800-A2 | Inhibitors of HIV reverse transcriptase | MERCK & CO. INC. (US) | 1991-12-27 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (13 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230365531-A1 | INHIBITORS OF HUMAN RESPIRATORY SYNCYTIAL VIRUS AND METAPNEUMO VIRUS | METAP1, SARS1, RTF1 | KDM4E 3953/4885RAB9A 573/4885PRKCI 3064/4885 |
| US-20230183219-A1 | CONDENSED SUBSTITUTED HYDROPYRROLES AS ANTAGONISTS OF THE MUSCARINIC ACETYLCHOLINE RECEPTOR M4 | CHRM3, CHRM2, CHRM4 | KDM4E 2342/4885RAB9A 2121/4885PRKCI 3559/4885 |
| US-20070078120-A1 | Novel piperidine derivative | LDLR, PRMT5, MSR1 | KDM4E 728/4885RAB9A 1776/4885PRKCI 1585/4885 |
| US-20070032525-A1 | Piperidine derivatives having ccr3 antagonism | CCR3, CCR1, CCR4 | KDM4E 3395/4885RAB9A 1505/4885PRKCI 3548/4885 |
| US-20070010509-A1 | Cycloamine ccr5 receptor antagonists | CCR5, CCR2, CCR1 | KDM4E 4818/4885RAB9A 2412/4885PRKCI 4044/4885 |
| US-20240216355-A1 | PHARMACEUTICAL COMPOSITIONS FOR USE IN THE PREVENTION AND TREATMENT OF A DISEASE OR DISORDER CAUSED BY OR ASSOCIATED WITH ONE OR MORE PREMATURE TERMINATION CODONS | UPF1, NSUN2, RTF2 | KDM4E 3979/4885RAB9A 3771/4885PRKCI 1659/4885 |
| US-20230183237-A1 | COMPETITIVE AND NONCOMPETITIVE INHIBITORS OF THE MUSCARINIC ACETYLCHOLINE RECEPTOR M5 | CHRM5, CHRM1, CHRM2 | KDM4E 1188/4885RAB9A 1907/4885PRKCI 4072/4885 |
| US-20070037851-A1 | Inhibits binding of CCR3 ligands such as eotaxins to their target cells; inhibits physiological effects of binding; therapeutic and prophylactic agents for asthma, rhinitis, dermatitis, urticaria, conjunctivitis, inflammatory bowel; tissue infiltration of eosinophils, basophils, activated T cells | CCR3, CCR1, CCR4 | KDM4E 3617/4885RAB9A 1790/4885PRKCI 2840/4885 |
| US-20070037855-A1 | Compounds for inhibiting beta-amyloid production and methods of identifying the compounds | APP, PSEN1, PSEN2 | KDM4E 4759/4885RAB9A 3592/4885PRKCI 513/4885 |
| US-20050159469-A1 | HIV protease inhibiting compounds | SERPINB1, HPN, DNPEP | KDM4E 3048/4885RAB9A 2012/4885PRKCI 3524/4885 |
| US-20230312499-A1 | CARBAMATE COMPOUNDS AND METHODS OF MAKING AND USING SAME | ABHD6, ABHD16A, RABL6 | KDM4E 473/4885RAB9A 458/4885PRKCI 3262/4885 |
| US-20230348418-A1 | ISOINDOLINONE COMPOUNDS | CYP4F2, AOC2, AOC3 | KDM4E 3578/4885RAB9A 3124/4885PRKCI 2340/4885 |
| US-11912682-B2 | Isoindolinone compounds | CYP4F2, AOC2, AOC3 | KDM4E 3666/4885RAB9A 3175/4885PRKCI 2386/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.